Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 501–600 of 3,116
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02623 · Cited by 17
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 27
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Haran, K., Johnson, C., Smith, P. L., Venable, Z., Kranyak, A. C., Bhutani, T., Jeon, C., & Liao, W. J. (2024) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s485061 · Cited by 34
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Patient Management Following Percutaneous Coronary Intervention
Wennberg, E., Abualsaud, A. O., & Eisenberg, M. J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101453 · Cited by 25
Cardiovascular Risk Factor Management After Hypertensive Disorders of Pregnancy
Lewey, J., Sheehan, M. M., Bello, N. A., & Levine, L. D. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005672 · Cited by 22
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Metabolic alliance: pharmacotherapy and exercise management of obesity
Butragueño, J., & Ruiz, J. R. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01006-7 · Cited by 18
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
Siddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 20
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Krychtiuk, K. A., Marquis‐Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., Leiter, L. A., Lópes, R. D., Prato, S. D., Jones, W. S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae006 · Cited by 21
GLP-1 receptor agonists in heart failure: how far to expand use?
Hage, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01763-x · Cited by 16
Berra, C., Manfrini, R., Bifari, F., Cipponeri, E., Ghelardi, R., Centofanti, L., Mortola, U., Lunati, E., Bucciarelli, L. G., Cimino, V., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107517 · Cited by 20
Schaefer, E. J., Asztalos, B. F., Vaisar, T., Diffenderfer, M. R., Brewer, H. B., Stock, E. O., & Kane, J. P. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01308-9 · Cited by 21
Lane, D. A., Andrade, J. G., Arbelo, E., Boriani, G., Hendriks, J., Lee, S., Lip, G. Y. H., Mant, J., & Middeldorp, M. E. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02166-x · Cited by 35
Hunter, T. M., Cao, D., FORRESTER, T. D., Brumm, J. F., & Chao, A. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16463 · Cited by 26
Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
Yun, J., Kim, K., Ahn, Y., Han, K., & Ko, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0310 · Cited by 29
Valensi, P. E. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02436-3 · Cited by 24
Management of obesity in menopause
Palacios, S., Chedraui, P. A., Sánchez‐Borrego, R., Coronado, P., Simoncini, T., Schauding, K., Hillard, T., & Nappi, R. E. (2024) · Climacteric · doi:10.1080/13697137.2024.2374760 · Cited by 19
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Eisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 48
Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Kawashima, J., Mumtaz, K., & Pawlik, T. M. (2025) · World Journal of Surgery · doi:10.1002/wjs.12484 · Cited by 21
Felix, N. S., Gauza, M. D. M., Bittar, V., Nogueira, A., Costa, T. A., Godoi, A., de Lucena, L. A., Gonçalves, O. R., Pinto, L. C. S., Tramujas, L., et al. (2025) · Cardiorenal Medicine · doi:10.1159/000543149 · Cited by 18
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
Advances in incretin-based therapeutics for obesity
ROSENKILDE, M. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00938-w · Cited by 17
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“…from the SELECT trial—which included over-weight patients—and the FLOW trial—which suggested a positive outcome mediated by improved renal function— support the hypothesis that the benefits of GLP-1 RAs in HF are likely multifactorial and only partially attributable to weight loss [37, 141].”
InfluentialTrajectories of cardiovascular ageing—from molecular mechanisms to clinical implementation
Ministrini, S., Wenzl, F. A., Lüscher, T. F., & Camici, G. G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae178 · Cited by 30
Lymperopoulos, A., Altsman, V. L., & Stoicovy, R. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157239 · Cited by 27
Pennings, N. J., Varney, C., Hines, S., Riley, B. A., Happel, P., Patel, S., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100172 · Cited by 25
When cardiovascular medicines should be discontinued
Krychtiuk, K. A., Gersh, B. J., Washam, J. B., & Granger, C. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae302 · Cited by 21
The Close Link Between Obesity and Cardiovascular Disease
Lee, H., Rhee, T., Choi, J. M., Choi, S., & Kim, D. W. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.005 · Cited by 18
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications
Nagel, K. E., Ramachandran, R., & Lipska, K. J. (2024) · Diabetes Care · doi:10.2337/dci23-0042 · Cited by 20
A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss
Tzoulis, P., Batavanis, M., & Baldeweg, S. E. (2024) · Cureus · doi:10.7759/cureus.59558 · Cited by 30
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
“While this approach provides broad applicability, it complicates direct comparisons between specific agents and optimal dosing strategies [78, 79].”
Abdulraheem, A., Abujaber, B. A., Ayers, L., Zureikat, Q. A., Bashiri, K., Almhanni, G., Altork, N. A., Afzal, U., Qarkash, D., Spyros, P., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11962-4 · Cited by 23
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
McIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 22
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
Are GLP-1s the first longevity drugs?
(2025) · Nature Biotechnology · doi:10.1038/s41587-025-02932-1 · Cited by 17
Mendonça, L., Moura, H., Castro‐Chaves, P., Neves, J. S., & Ferreira, J. P. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000584 · Cited by 21
Han, Y., Xu, H., Yao, X., Li, Z., Zhu, C., Li, X., Chen, B., & Sun, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1737662 · Cited by 23
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
“Among the outcomes of interest, semaglutide was associated with statistically significant reductions in all-cause mortality, CV mortality or HF hospitalization/event, non-fatal MI, MACE, and the composite kidney outcome [46].”
Pharmacological management of testosterone deficiency in men current advances and future directions
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2366505 · Cited by 19
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 22
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 16
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
Neves, J. S., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.026 · Cited by 16
Inflammation in coronary atherosclerosis: diagnosis and treatment
Occhipinti, G., Brugaletta, S., Abbate, A., Pedicino, D., Buono, M. G. D., Vinci, R., Biondi‐Zoccai, G., Sabaté, M., Angiolillo, D. J., & Liuzzo, G. (2025) · Heart · doi:10.1136/heartjnl-2024-325408 · Cited by 16
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Chang, Y., Chi, K., Song, J., & Lin, H.-M. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.07.010 · Cited by 18
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Bellos, I., Λάγιου, Π., Benetou, V., & Marinaki, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206181 · Cited by 19
Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Hohl, A., Ronsoni, M. F., Pasqualotto, T., Moraes, F. C. A. D., Hespanhol, L., Figueiredo Watanabe, J. M., Lütkemeyer, C., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100321 · Cited by 15
“The effects of other GLP-1 RAs on cardiovascular outcomes remain to be evaluated in patients with obesity or overweight, however, the results of the SELECT trial highlight the importance of treating obesity to reduce cardiovascular risk [33].”
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
Simon, J. A., Davis, S. R., Hirschberg, A. L., Kiesel, L., Pompei, L. D. M., Reginster, J., Simoncini, T., & Hillard, T. (2025) · Climacteric · doi:10.1080/13697137.2025.2457993 · Cited by 28
Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70143 · Cited by 17
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100245 · Cited by 26
Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications
Young, G. M., Bansal, K., Riello, R. J., Clark, K. A. A., Dhruva, S. S., Faridi, K. F., & Desai, N. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.12437 · Cited by 16
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF
Capone, F., Nambiar, N., & Schiattarella, G. G. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001117 · Cited by 15
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 26
Self-citationShantaram, D., Rima, X. Y., Bradley, D. P., Liu, J. Z., Wright, V. P., AMARI, A., Jalilvand, A., Rottinghaus, J., Fernandes, J. M., Smith, A. J., et al. (2025) · Diabetes · doi:10.2337/db24-0861 · Cited by 18
El‐Sheikh, M., Caidi, N. O. E., Kandiah, A., Tonning, S. H., Taraldsen, I. A., Wisborg, F. D., Andersen, O., Hove, J. D., & Grand, J. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.35 · Cited by 20
Sun, P., Wan, Z., & Liu, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70020 · Cited by 29
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 20
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
Emerging Technologies and Future Directions in Interorgan Crosstalk Cardiometabolic Research
Bae, H., Nguyen, C. M., Ruiz‐Orera, J., Mills, N. L., Snyder, M. P., Jang, C., Shah, S. H., Hübner, N., & Seldin, M. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325515 · Cited by 16
Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13816 · Cited by 17
Okazaki, R. A., Rizvi, S. H. M., Lyons, R., Behrooz, L., & Hamburg, N. M. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00793.2024 · Cited by 19
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Greiner, T. U., Koh, A., Peris, E., Bergentall, M., Johansson, M., Hansson, G. C., Drucker, D. J., & Bäckhed, F. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101924 · Cited by 21
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“Studies have demonstrated cardiovascular benefits with GLP-1 based therapies in patients with pre-existing cardiovascular disease or cardiovascular risk factors [29,43], including patients with heart failure with preserved ejection fraction and obesity [44,45].”
Min, K.-D., Matsumoto, Y., Asakura, M., & Ishihara, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14811 · Cited by 16
Rasouli, N., Arslan, E. G., Catarig, A., Houlind, K. C., Ludvik, B. H., Nordanstig, J., Sourij, H., Thomas, S., Verma, S., & Bonaca, M. P. (2025) · Diabetes Care · doi:10.2337/dc25-1082 · Cited by 18
Jorge, A. M., Patel, A. V., Zhou, B., Zhang, L., & Choi, H. K. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43403 · Cited by 19
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Borlaug, B. A., Holse, C., Jung, M. H., Lincoff, A. M., Mulvagh, S. L., Stærk‐Østergaard, J., Tuttle, K. R., & Petrie, M. C. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102712 · Cited by 25
Self-citationTreat Obesity to Treat Type 2 Diabetes Mellitus
Sulu, C., & Yumuk, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01536-3 · Cited by 24
Velji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
Sio, V. D., Gragnano, F., Capolongo, A., Guarnaccia, N., Maddaluna, P., Acerbo, V., Galli, M., Berteotti, M., Sperlongano, S., Cesaro, A., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133028 · Cited by 15
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
Chen, J., Zhang, Q., Wu, Q., Zhang, X., Xiang, Z., Zhu, S., Dai, T., & Si, Y.-X. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70151 · Cited by 17
Inoue, K., Saliba, D., Gotanda, H., Moin, T., Mangione, C. M., Klomhaus, A. M., & Tsugawa, Y. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02648 · Cited by 22
Wilson, L., Zhao, Z., Divino, V. M., Bassan, M., Hartaigh, B. Ó., Stensen, S., & Özer, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70436 · Cited by 22
“7 These beneficial CV effects of semaglutide were observed early after treatment initiation, with the first statistically significant differences observed at Day 20 and sustained from Day 86 through the end of follow-up.”
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
